Bio-Tech Analyst Jason Napadano Values the Company At .24 Currently
From today's Seeking Alpha article:
In a previous article on Amarantus BioScience Holdings, Inc., I concluded that MANF was worth an estimated $42 million in value over at the Amarantus Therapeutics division given all the available scientific data. As such, I see the entire company worth an estimated $92 million. Given an estimated ~390 million share count, that equates to a target price of $0.24 per share. I expect the value of Amarantus to rise as investors become more familiar with LymPro and the company begins to generate the necessary data for a CLIA filing.